Summary of Orchestra BioMed FY Conference Call Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Biomedical innovation with two pivotal stage cardiovascular programs: - **Virtue Sirolimus AngioInfusion Balloon** for coronary artery disease - **Atrioventricular Interval Modulation (AVIM) therapy** for hypertensive heart disease in high-risk patients, partnered with Medtronic [7][36] Key Programs and Developments Virtue Sirolimus AngioInfusion Balloon - **Current Status**: Enrolling pivotal trials, with expectations to finish the BACKBEAT trial this year and data anticipated shortly thereafter [8] - **Market Potential**: Positioned in an almost $8 billion market, with a paradigm shift from drug-eluting stents to drug-eluting balloons [18][19] - **Competitive Landscape**: Currently, only Boston Scientific has a commercial coronary drug-coated balloon in the U.S. [18] - **Clinical Advantage**: Virtue aims to deliver better clinical results with a proprietary drug delivery method that encapsulates sirolimus, leading to significantly higher drug levels compared to existing products [25][26] Atrioventricular Interval Modulation (AVIM) Therapy - **Trial Progress**: Enrollment is accelerating with over 100 sites engaged, and protocol changes have improved participation [38] - **Therapeutic Impact**: AVIM therapy shows immediate blood pressure reduction in patients, with significant double-digit drops observed [40][41] - **Market Opportunity**: Estimated 1 million patients worldwide receiving pacemakers annually could benefit from AVIM therapy [42] - **Regulatory Path**: Medtronic is responsible for regulatory and manufacturing aspects, with a focus on U.S. market approval expected around 2028 [51][54] Financial and Strategic Partnerships - **Recent Financing**: Secured over $60 million from partners including Medtronic and Terumo, minimizing equity dilution and providing a strong balance sheet [14][15] - **Business Model**: Focused on leveraging strategic partnerships for commercialization, with significant royalty interests from products [7] Market Dynamics and Clinical Insights - **Physician Engagement**: High enthusiasm from physicians regarding the unique delivery method of Virtue and the potential clinical advantages [34] - **Clinical Data**: Ongoing education for physicians about the differences between sirolimus and paclitaxel, emphasizing the benefits of sirolimus in healing vessels [33] - **Hypertension and Heart Failure**: AVIM therapy targets a unique patient population with uncontrolled systolic hypertension, potentially impacting quality of life and cardiac function [60][63] Conclusion - **Outlook**: Orchestra BioMed is well-positioned for future growth with innovative products addressing significant market needs, strong partnerships, and a clear path towards commercialization [36][64]

Core Insights - Orchestra BioMed Holdings, Inc. presented key clinical insights on AVIM therapy for high-risk hypertension at the CSI 2025 Meeting, emphasizing its potential to address hypertensive heart disease, a significant cardiovascular syndrome affecting an aging population [1][6] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through risk-reward sharing partnerships with leading medical device companies [5] - The company’s lead product candidate is AVIM therapy, designed for hypertension, which is a leading risk factor for mortality worldwide [5][8] AVIM Therapy Insights - AVIM therapy is a novel, device-based approach specifically targeting patients with hypertensive heart disease, who are at increased risk for major adverse cardiac events and currently lack sufficient therapeutic options [2][3] - The therapy aims to reduce cardiac preload and modulate autonomic nervous system responses to lower blood pressure and improve cardiovascular function, representing a potential paradigm shift in blood pressure management [3][4] Clinical Data and Studies - Pilot studies have shown that AVIM therapy resulted in net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [10] - The BACKBEAT global pivotal study is currently enrolling patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker, in collaboration with Medtronic [7][10] Market Opportunity - Hypertensive heart disease affects over 7.7 million patients in the U.S., highlighting a significant market opportunity for AVIM therapy, especially given its recent FDA Breakthrough Device Designation [6][10]